https://www.nasdaq.com/press-release/allena-pharmaceuticals-provides-clinical-and-corporate-update-2022-01-04
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-participate-in-the-stifel-2021-virtual-healthcare
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-third-quarter-2021-financial-results-and-recent
https://www.nasdaq.com/press-release/allena-pharmaceuticals-receives-fast-track-designation-from-fda-for-the-development
https://www.nasdaq.com/press-release/allena-pharmaceuticals-commences-dosing-of-gout-patients-in-second-phase-2a-trial-of
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-participate-in-h.c.-wainwrights-23rd-annual-global
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-second-quarter-2021-financial-results-and-recent
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-participate-in-the-12th-annual-wedbush-pacgrow-healthcare
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-%2428-million-registered-direct-offering-priced-at-the
https://www.nasdaq.com/press-release/allena-pharmaceuticals-provides-update-on-clinical-development-programs-2021-07-12
https://www.nasdaq.com/press-release/allena-pharmaceuticals-inc.-to-present-at-the-ladenburg-thalmann-2021-virtual
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-1
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-host-key-opinion-leader-webinar-focused-on-alln-346-for-the
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-0
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4
https://www.nasdaq.com/press-release/allena-pharmaceuticals-appoints-mark-j.-fitzpatrick-to-its-board-of-directors-2021-04
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-present-at-upcoming-investor-conferences-in-march-2021-02
https://www.nasdaq.com/press-release/allena-pharmaceuticals-appoints-richard-d.-katz-m.d.-as-chief-financial-officer-2021
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-present-at-upcoming-investor-conferences-in-january-2021-01
https://www.nasdaq.com/press-release/allena-pharmaceuticals-increases-previously-announced-bought-deal-to-%2413.0-million
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-%2410.0-million-bought-deal-offering-2020-12-01
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-appointment-of-david-j.-clark-m.d.-m.r.c.p.-as-chief
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-initial-data-from-phase-1-trial-of-alln-346-2020-11
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-present-virtually-at-evercore-isi-3rd-annual-healthconx
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-participate-virtually-in-upcoming-investor-conferences-in
https://www.nasdaq.com/press-release/allena-pharmaceuticals-appoints-ann-miller-m.d.-to-its-board-of-directors-2020-10-05
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-%2425-million-strategic-convertible-debt-financing
https://www.nasdaq.com/press-release/allena-pharmaceuticals-doses-first-subject-in-phase-1-clinical-trial-of-alln-346-in
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-present-virtually-at-upcoming-investor-conferences-in
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-present-at-2020-wedbush-pacgrow-healthcare-virtual
https://www.nasdaq.com/press-release/allena-pharmaceuticals-increases-previously-announced-bought-deal-to-%246.7-million
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-%245.0-million-bought-deal-offering-2020-07-27
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-%2415.0-million-registered-direct-offering-priced-at
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-2020-05
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-fourth-quarter-2019-and-full-year-2019-financial
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-present-at-40th-annual-cowen-co.-health-care-conference
https://www.nasdaq.com/press-release/allena-pharmaceuticals-announces-streamlined-design-for-urirox-2-second-pivotal
https://www.nasdaq.com/press-release/allena-pharmaceuticals-provides-updates-on-reloxaliase-development-program-and
https://www.nasdaq.com/press-release/allena-pharmaceuticals-to-present-at-evercore-isi-2nd-annual-healthconx-conference
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/allena-pharmaceuticals-reports-positive-reloxaliase-topline-results-from-urirox-1
